vs

Side-by-side financial comparison of Royalty Pharma plc (RPRX) and Red Rock Resorts, Inc. (RRR). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $507.3M, roughly 1.2× Red Rock Resorts, Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs 16.3%, a 18.1% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 1.9%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 2.1%).

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

Wynn Resorts, Limited is an American publicly traded corporation based in Paradise, Nevada, that is a developer and operator of high-end hotels and casinos. It was founded in 2002 by former Mirage Resorts Chairman and CEO Steve Wynn and is now run by CEO Craig Billings. As of 2020, the company has developed six properties.

RPRX vs RRR — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.2× larger
RPRX
$622.0M
$507.3M
RRR
Growing faster (revenue YoY)
RPRX
RPRX
+2.9% gap
RPRX
4.8%
1.9%
RRR
Higher net margin
RPRX
RPRX
18.1% more per $
RPRX
34.4%
16.3%
RRR
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
2.1%
RRR

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
RPRX
RPRX
RRR
RRR
Revenue
$622.0M
$507.3M
Net Profit
$214.2M
$82.7M
Gross Margin
Operating Margin
62.4%
28.3%
Net Margin
34.4%
16.3%
Revenue YoY
4.8%
1.9%
Net Profit YoY
2.9%
-3.8%
EPS (diluted)
$0.49
$0.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RPRX
RPRX
RRR
RRR
Q1 26
$507.3M
Q4 25
$622.0M
$511.8M
Q3 25
$609.3M
$475.6M
Q2 25
$578.7M
$526.3M
Q1 25
$568.2M
$497.9M
Q4 24
$593.6M
$495.7M
Q3 24
$564.7M
$468.0M
Q2 24
$537.3M
$486.4M
Net Profit
RPRX
RPRX
RRR
RRR
Q1 26
$82.7M
Q4 25
$214.2M
$44.7M
Q3 25
$288.2M
$42.3M
Q2 25
$30.2M
$56.4M
Q1 25
$238.3M
$44.7M
Q4 24
$208.2M
$46.6M
Q3 24
$544.0M
$29.0M
Q2 24
$102.0M
$35.7M
Operating Margin
RPRX
RPRX
RRR
RRR
Q1 26
28.3%
Q4 25
62.4%
28.1%
Q3 25
70.1%
27.6%
Q2 25
36.3%
31.9%
Q1 25
94.0%
31.0%
Q4 24
60.9%
28.7%
Q3 24
27.9%
Q2 24
50.2%
28.8%
Net Margin
RPRX
RPRX
RRR
RRR
Q1 26
16.3%
Q4 25
34.4%
8.7%
Q3 25
47.3%
8.9%
Q2 25
5.2%
10.7%
Q1 25
41.9%
9.0%
Q4 24
35.1%
9.4%
Q3 24
96.3%
6.2%
Q2 24
19.0%
7.3%
EPS (diluted)
RPRX
RPRX
RRR
RRR
Q1 26
$0.73
Q4 25
$0.49
$0.74
Q3 25
$0.67
$0.68
Q2 25
$0.07
$0.95
Q1 25
$0.55
$0.75
Q4 24
$0.46
$0.78
Q3 24
$1.21
$0.48
Q2 24
$0.23
$0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RPRX
RPRX
RRR
RRR
Cash + ST InvestmentsLiquidity on hand
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$9.7B
Total Assets
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RPRX
RPRX
RRR
RRR
Q1 26
Q4 25
$618.7M
$142.5M
Q3 25
$938.9M
$129.8M
Q2 25
$631.9M
$145.2M
Q1 25
$1.1B
$150.6M
Q4 24
$929.0M
$164.4M
Q3 24
$950.1M
$117.5M
Q2 24
$1.8B
$136.4M
Total Debt
RPRX
RPRX
RRR
RRR
Q1 26
Q4 25
$9.0B
$3.4B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
$3.4B
Q3 24
$7.6B
Q2 24
$7.6B
Stockholders' Equity
RPRX
RPRX
RRR
RRR
Q1 26
Q4 25
$9.7B
$208.3M
Q3 25
$9.6B
$219.6M
Q2 25
$9.5B
$203.4M
Q1 25
$9.8B
$247.1M
Q4 24
$10.3B
$215.1M
Q3 24
$10.3B
$175.5M
Q2 24
$9.8B
$159.0M
Total Assets
RPRX
RPRX
RRR
RRR
Q1 26
Q4 25
$19.6B
$4.2B
Q3 25
$19.3B
$4.1B
Q2 25
$18.3B
$4.0B
Q1 25
$17.6B
$4.1B
Q4 24
$18.2B
$4.0B
Q3 24
$18.0B
$4.0B
Q2 24
$17.7B
$4.0B
Debt / Equity
RPRX
RPRX
RRR
RRR
Q1 26
Q4 25
0.92×
16.30×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
15.84×
Q3 24
0.74×
Q2 24
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RPRX
RPRX
RRR
RRR
Operating Cash FlowLast quarter
$827.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RPRX
RPRX
RRR
RRR
Q1 26
Q4 25
$827.1M
$156.6M
Q3 25
$702.6M
$168.3M
Q2 25
$364.0M
$158.4M
Q1 25
$596.1M
$126.2M
Q4 24
$742.5M
$148.2M
Q3 24
$703.6M
$131.0M
Q2 24
$658.2M
$142.5M
Free Cash Flow
RPRX
RPRX
RRR
RRR
Q1 26
Q4 25
$77.7M
Q3 25
$74.6M
Q2 25
$80.3M
Q1 25
$58.0M
Q4 24
$121.4M
Q3 24
$50.7M
Q2 24
$64.0M
FCF Margin
RPRX
RPRX
RRR
RRR
Q1 26
Q4 25
15.2%
Q3 25
15.7%
Q2 25
15.3%
Q1 25
11.6%
Q4 24
24.5%
Q3 24
10.8%
Q2 24
13.1%
Capex Intensity
RPRX
RPRX
RRR
RRR
Q1 26
Q4 25
15.4%
Q3 25
19.7%
Q2 25
14.9%
Q1 25
13.7%
Q4 24
5.4%
Q3 24
17.2%
Q2 24
16.2%
Cash Conversion
RPRX
RPRX
RRR
RRR
Q1 26
Q4 25
3.86×
3.51×
Q3 25
2.44×
3.98×
Q2 25
12.06×
2.81×
Q1 25
2.50×
2.82×
Q4 24
3.57×
3.18×
Q3 24
1.29×
4.53×
Q2 24
6.45×
4.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

RRR
RRR

Casino$340.5M67%
Food and beverage$90.3M18%
Room$45.5M9%
Other$26.2M5%
Native American management and development fees$4.7M1%

Related Comparisons